These data imply that, in translation from our proof-of-concept results to the clinic, local liver application of the treatment would assure a specific effect on hepatocellular carcinoma cells but not an off-target effect of normal liver cells (as they do not express TRPV2 protein), and no other tissues, by virtue of its local application. Here, TRPV2 is linked to hepatocellular carcinoma.